Creating Confidence in Antibody Drug Conjugates (ADCs) Characterization through a Combined and Orthogonal Analytics Approach: Ligand Binding and Live-Cell Analysis eBook
Last updated: October 2024
Overview
Antibody Drug Conjugates (ADCs) are among the fastest growing class of biologics and are developed as a combination of mAb and highly potent cytotoxic molecules (drugs). ADCs are cancer therapeutic agents comprised of an antibody, a linker, and a small-molecule payload. The specificity of the antibody is used to deliver the toxic payload directly to tumor cells, minimizing damage to healthy cells.
Our latest eBook explores the integration of ligand binding and live-cell analysis for comprehensive ADC characterization with an orthogonal analytics approach that offers a robust method for selecting optimal candidates.
- Document type: eBook
- Page count: 38
- Read time: 20 minutes
Key Takeaways
- Essential ADC Building Blocks and Success Strategies
- Maximize Efficiency and Cost-Effectiveness
Reduce drug discovery time with high-throughput capabilities and real-time data acquisition. Sartorius solutions minimize costs and resource usage through miniaturization and efficient processes - Insights Into Projected Growth of the ADC Market
- Real-World Applications
Case studies like Trastuzumab, Kadcyla®, and Enhertu® show the impact of structural differences on efficacy. Learn about functional characterization studies on Antibody-Dependent Cellular Cytotoxicity (ADCC) and ADC internalization using Sartorius platforms.
